Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2/3 1Phase 2 1Phase 1 1

Status

Withdrawn 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Colorectal Neoplasms 6Carcinoma, Hepatocellular 5Head and Neck Neoplasms 4Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Neoplasms, Squamous Cell 2Glioblastoma 2Colonic Neoplasms 2Uterine Cervical Neoplasms 1Urinary Incontinence 1Tuberous Sclerosis 1Sarcoma 1Recurrent respiratory papillomatosis 1Recurrence 1Rectal Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precancerous Conditions 1Postoperative Complications 1Papillomavirus Infections 1Papilloma 1Ovarian Neoplasms 1Orgasm 1Oligodendroglioma 1Neoplasms 1Neoplasm Metastasis 1Myasthenia Gravis 1Melanoma 1Medication Adherence 1

Interventions

Taxes 1Neoadjuvant Therapy 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Withdrawn × Inflammatory Breast Neoplasms × Clear all
NCT00397761 2021-02-17

Capecitabine and Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) in Treating Women Undergoing Surgery for Stage II or Stage III Breast Cancer

Medstar Health Research Institute

Phase 2/3 Withdrawn
Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡